Leveraging digital tools to support recovery from substance use disorder during the COVID-19 pandemic response.
COVID-19
Digital health
Substance use disorder
Telehealth
Wearable
mHealth
Journal
Journal of substance abuse treatment
ISSN: 1873-6483
Titre abrégé: J Subst Abuse Treat
Pays: United States
ID NLM: 8500909
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
received:
05
06
2020
revised:
07
10
2020
accepted:
19
11
2020
pubmed:
12
12
2020
medline:
17
4
2021
entrez:
11
12
2020
Statut:
ppublish
Résumé
Treatment for substance use disorder (SUD) during the COVID-19 pandemic poses unique challenges, both due to direct effects from the illness, and indirect effects from the physical measures needed to "flatten the curve." Stress, isolation, lack of structure, limited access to physical and mental health care, and changes in treatment paradigms all increase risk of return to drug use events and pose barriers to recovery for people with SUDs. The pandemic has forced treatment providers and facilities to rapidly adapt to address these threats while redesigning their structure to accommodate physical distancing regulations. Digital health interventions can function without the need for physical proximity. Clinicians can use digital health intervention, such as telehealth, wearables, mobile applications, and other remote monitoring devices, to convert in-person care to remote-based care, and they can leverage these tools to address some of the pandemic-specific challenges to treatment. The current pandemic provides the opportunity to rapidly explore the advantages and limitations of these technologies in the care of individuals with SUD.
Identifiants
pubmed: 33303253
pii: S0740-5472(20)30483-9
doi: 10.1016/j.jsat.2020.108226
pmc: PMC8005450
mid: NIHMS1653018
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
108226Subventions
Organisme : NIDA NIH HHS
ID : K23 DA045242
Pays : United States
Organisme : NIDA NIH HHS
ID : L30 DA038357
Pays : United States
Organisme : NIDA NIH HHS
ID : R44 DA046151
Pays : United States
Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Références
Ann Intern Med. 2020 Jul 7;173(1):59-60
pubmed: 32240291
Drug Alcohol Depend. 2020 Oct 1;215:108201
pubmed: 32777691
Drug Alcohol Depend. 2020 Apr 1;209:107929
pubmed: 32193048
J Addict Med. 2020 Jul/Aug;14(4):e6-e7
pubmed: 32404651
Addiction. 2017 Jun;112(6):1025-1035
pubmed: 28107772
Psychol Addict Behav. 2016 Feb;30(1):1-11
pubmed: 26618796
JAMA Netw Open. 2020 Sep 1;3(9):e2022942
pubmed: 32990735
Ann Intern Med. 2020 Jul 7;173(1):61-62
pubmed: 32240293
Lancet Psychiatry. 2020 May;7(5):390-391
pubmed: 32353270
J Dual Diagn. 2017 Apr-Jun;13(2):144-156
pubmed: 28045601
Harm Reduct J. 2020 May 6;17(1):26
pubmed: 32375887
JAMA. 2013 Aug 7;310(5):507-18
pubmed: 23925621
JMIR Mhealth Uhealth. 2017 Jul 07;5(7):e90
pubmed: 28687533
J Subst Abuse Treat. 2019 Jun;101:38-49
pubmed: 31006553
Subst Use Misuse. 2009;44(12):1749-67
pubmed: 19895305
Mhealth. 2018 Jul 30;4:29
pubmed: 30148142
Soc Sci Med. 2017 Oct;190:29-37
pubmed: 28837863
Psychiatr Serv. 2014 Nov 1;65(11):1392-5
pubmed: 25219795